VF
LCTX icon

Virtu Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Virtu Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48K Sell
36,280
-27,527
-43% -$38K ﹤0.01% 1229
2026
Q1 		$101K Buy
+63,807
New +$108K ﹤0.01% 1190
2024
Q3 		– Sell
-78,454
Closed -$78K – 1645
2024
Q2 		$78K Buy
+78,454
New +$86.7K 0.01% 852
2023
Q2 		– Sell
-17,521
Closed -$26K – 1791
2023
Q1 		$26K Sell
17,521
-26,921
-61% -$37.6K ﹤0.01% 1197
2022
Q4 		$52K Buy
44,442
+34,414
+343% +$43.4K 0.01% 1074
2022
Q3 		$11K Sell
10,028
-3,352
-25% -$4.92K ﹤0.01% 1506
2022
Q2 		$21K Buy
+13,380
New +$17.6K ﹤0.01% 1320
2021
Q3 		– Sell
-54,131
Closed -$154K – 1746
2021
Q2 		$154K Buy
+54,131
New +$140K 0.02% 1081
2020
Q4 		– Sell
-40,318
Closed -$38K – 1620
2020
Q3 		$38K Sell
40,318
-37,724
-48% -$33.3K 0.01% 849
2020
Q2 		$68K Buy
+78,042
New +$68.7K 0.01% 958
2019
Q1 		– Sell
-34,884
Closed -$32K – 1657
2018
Q4 		$32K Buy
+34,884
New +$53.4K ﹤0.01% 1329
2018
Q1 		– Sell
-119,836
Closed -$225K – 2295
2017
Q4 		$225K Buy
119,836
+101,293
+546% +$221K 0.01% 1546
2017
Q3 		$46K Buy
+18,543
New +$46K ﹤0.01% 2240

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Virtu Financial's LCTX Position: Q2 2026 in Review

Virtu Financial reduced its Lineage Cell Therapeutics (LCTX) stake by 43% in Q2 2026, selling an estimated $38K and leaving 36,280 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

Virtu Financial first reported a position in LCTX in Q3 2017 and has held it in 13 quarters since. The position peaked at $225K in Q4 2017. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Virtu Financial held 36,280 shares of Lineage Cell Therapeutics worth $48K as of Q2 2026.
  • Virtu Financial sold 27,527 Lineage Cell Therapeutics shares in Q2 2026, an estimated $38K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1229 holding.
  • Virtu Financial first reported a position in Lineage Cell Therapeutics in Q3 2017 and has held it in 13 quarters since.
  • Virtu Financial's Lineage Cell Therapeutics position peaked at $225K in Q4 2017.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.